Why Is ABBV Down Today?
AbbVie reported its Q4 2025 earnings, beating Wall Street expectations on both revenue and earnings per share. Despite the positive financial performance, the stock is experiencing a significant decline as investors digest the detailed results and forward guidance.
- AbbVie's Q4 earnings beat analyst expectations, with strong performance in immunology drug sales. The company reported robust revenue growth, particularly in newer immunology drug segments, signaling continued market strength.
- Analysts are currently evaluating the company's 2026 profit forecast, which was projected above previous market estimates. The mixed reaction suggests investors are carefully analyzing the long-term growth potential.
- Humira, the company's flagship drug, continues to face potential market challenges with increasing competition and patent expirations. This ongoing pressure could impact future revenue streams and market positioning.
- The broader pharmaceutical market is experiencing volatility, with investors closely monitoring earnings reports and potential regulatory changes. AbbVie's performance is being evaluated in this complex market context.
- Stock is currently down $8.55 (3.79%), indicating potential investor concerns about the company's near-term growth trajectory and competitive landscape in the immunology drug market.
- The company's diversified portfolio and strong performance in newer drug segments present potential opportunities for future growth and market expansion.
Bottom line for investors: AbbVie demonstrates solid financial fundamentals with promising immunology drug sales, but faces ongoing challenges in maintaining market leadership. Investors should monitor the company's strategy for new drug development and its ability to offset potential Humira revenue declines.
Key Statistics
Market Cap
$395.66B
P/E Ratio
165.72
Dividend Yield
0.03%
Volume
15,319,437
Avg Volume
5,963,869
52-Week High
$244.81
52-Week Low
$164.39
About AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Analyst Ratings
View All →
Avg Price Target
$258.83
(+19.2% upside)
| Date | Firm | Rating |
|---|---|---|
| Jan 27, 2026 | Citigroup | |
| Jan 8, 2026 | Wolfe Research | |
| Dec 12, 2025 | Morgan Stanley | |
| Dec 10, 2025 | HSBC | |
| Nov 7, 2025 | UBS |
